Immune Response Surveillance and Potential Booster Vaccines for Patients Who Have Received HER2-pulsed DC1 Vaccine

H. Lee Moffitt Cancer Center and Research Institute1 site in 1 country16 target enrollmentJanuary 10, 2019

ConditionsBreast Cancer HER2-positive Breast Cancer HER-2 Gene Amplification HER2 Positive Breast Carcinoma HER-2 Protein Overexpression Breast Cancer, Male Breast Cancer Female

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Breast Cancer
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Enrollment: 16
Locations: 1
Primary Endpoint: HER2 DC1 Vaccine Regimen
Status: Terminated
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to learn more about how to treat patients with a diagnosis of diagnosis of Human Epidermal Growth Factor Receptor 2/neu (HER-2/neu) positive breast cancer in the past, who were previously treated with HER-2/neu-directed dendritic cells (DC) vaccines.

There is evidence that the use of anti-HER2 dendritic cell (DC) study vaccines could improve response to breast cancer therapy and be an important step in the prevention of recurrence.

This study will use a Dendritic Cell Type 1 (DC1) vaccine which is a HER2-sensitized dendritic cell (DC) study vaccine. Dendritic cells are immune cells that can tell the participant's immune system to fight infection. This study vaccine will be made from the participant's blood cells collected from a procedure called leukapheresis.

Registry

clinicaltrials.gov

Start Date

January 10, 2019

End Date

April 11, 2022

Last Updated

4 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with a diagnosis of nonmetastatic or metastatic breast cancer in complete clinicla response classic HER2pos (ie, IHC 3+ or FISHpos) breast cancer (BC) who have previously been vaccinated with DC1 HER2-pulsed vaccines on any of several prior clinical trials for ductal carcinoma in situ (DCIS) or inflammatory breast cancer (IBC) are eligible; however, we also allowed HER2 2+ patients in many of these prior trials and they will also be allowed to participate in this trial. Note: HER2pos BC is defined by tumor tissue HER2 overexpression and or tumor HER2 amplification. The lack of HER2 overexpression by IHC is defined as 0 or 1+ whereas overexpression is defined as 3+. In the event of equivocal IHC, 2+, the tumor must be gene-amplified by fluorescent in situ hybridization (FISH) performed upon the primary tumor or metastatic lesion (ratio \> 2 and HER2 copy number \> 4 define HER2negdisease).
•Patients with nonmetastatic HER posBC must have completed all standard-of-care treatment for nonmetastatic BC (e.g., surgery, chemotherapy, radiation therapy, and HER2-targeted therapy). Note: antiestrogen therapy is permitted while on trial. Note: antiestrogen therapy is permitted while on trial.
•Patients with diagnosis of metastatic HER2 pos breast cancer must have complete tumor response to current treatment per RECIST 1.1 and completed all standard-of-care chemotherapy. Note: maintenance treatment with approved HER2-targeted agents and/or antiestrogen therapy is permitted while on trial.
•Age ≥ 18 years.
•Eastern Cooperative Oncology Group (ECOG) performance status 0 or
•Participants must have normal organ and marrow function within 2 weeks of registration.
•For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose.
•Must have the ability to understand and the willingness to sign a written informed consent prior to registration on study.

Exclusion Criteria

•Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, congenital prolonged QT syndrome, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
•Uncontrolled congenital or acquired immune deficiency that is requiring treatment that would interfere with study treatment will not be allowed on study. Topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption) are allowed. Patients who have received systemic corticosteroids ≤ 30 days prior to starting study drug will be excluded.
•No other prior malignancy is allowed except for the following:
•Adequately treated basal cell or squamous cell skin cancer
•In situ cervical cancer
•Any other cancer from which the patient has been disease free for at least 3 years.
•Pregnant or breast feeding.
•Known to be HIV positive.
•Known current or a history of hepatitis B or C virus, including chronic and dormant states, unless disease has been treated and confirmed cleared.
•Major surgery within 4 weeks of initiation of study drug.

Outcomes

Primary Outcomes

HER2 DC1 Vaccine Regimen

Time Frame: Up to 16 months

Investigators will assess the feasibility of participants receiving the six-booster regimen if 11/15 randomized to Arm D complete all 6 booster injections.

Secondary Outcomes

HER2 Immunity with 3 Booster Regimen at 18 months(At 18 months after first dose)
Rate of Treatment Emergent Adverse Events of 6 Dose Regimen(Up to 5 years)
Overall Survival(Up to 5 Years)
Disease Free Survival(Up to 5 Years)
Progression Free Survival(Up to 5 Years)
HER2 Immunity with 6 Booster Regimen at 18 months(At 18 months after first dose)
HER2 Immunity with 3 Booster Regimen at 10 months(At 10 months after first dose)
HER2 Immunity with 6 Booster Regimen at 10 months(At 10 months after first dose)
Rate of Treatment Emergent Adverse Events of 3 Dose Regimen(Up to 5 years)